AzTrials
AzTrials

Cervical LesionNCT04735718

Clinical Investigation To Evaluate Cerviron Ovules® in Cervix Lesions Postoperative Care

A study testing Cerviron in people with Cervical Lesion, run by Perfect Care Distribution at 3 sites in Romania.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in postoperative care in patients that… Read more about this study

Who is it for?
Ages 18 to 65 years, women only
Conditions the study is for
Cervical Lesion
What is being tested?
Cerviron
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
27 participants
Where
3 sitesRomania
Study dates
1 Aug 2021to 16 Jan 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Adult females, aged 18 years to 65 years;
  • Subjects presenting benign, ectopic, cervix lesions that were excised no later than 7 days before the Screening Visit, confirmed by colposcopy;
  • Subjects presenting a normal cervical cytology report, e.g. Negative for Intraepithelial Lesions or Malignancy (NILM) or slightly modified to Atypical Squamous Cells of Undetermined Significance (ASC-US) in the last 6 months;
  • Subjects willing to provide signed informed consent to clinical investigation participation.

Who cannot join

  • Previous history of any malignancy, particularly those that are prone to metastases, including breast, melanoma, gestational trophoblastic disease, and high-grade malignancies of the gastrointestinal tract or lung;
  • Subjects with undiagnosed abnormal genital bleeding;
  • Subject with vulvar, vaginal or cervical cancer;
  • Subjects presenting an abnormal cytology report, e.g. cervical intraepithelial neoplasia" (CIN) or "adenocarcinoma in situ" (AIS) in the last 6 months;
  • Watery or foul discharge;
  • Subjects with HIV or other immunodeficiency;
Show all 11Show fewer
  • Use of spermicides;
  • Use of diaphragm;
  • Concomitant topical or systemic anti-infective treatment;
  • Unable to comply with visit procedures;
  • Subjects included in other clinical investigations with similar objectives

Trial locations and contacts

3 sites in 1 country.

Romania3 sites
  • Institutul National pentru Sanatatea Mamei si Copilului " Alessandrescu-Rusescu"

    Bucharest

  • Centrul Medical MIȘCĂ

    Timișoara

  • Spitalul Clinic Județean de Urgență "Pius Brinzeu"

    Timișoara

Other trials in Romania

About this study

Official title: A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care

CYRON is a Prospective, Open-Label, Pilot, Multicentric Clinical Investigation to Evaluate the Performance and Safety of Cerviron® Ovules in Cervix Lesions Postoperative Care. The primary objective is to assess the therapeutic performance and tolerability of Cerviron® Ovules in postoperative care in patients that underwent surgical removal of benign, cervical lesions. The secondary objective of this clinical investigation is the assessment of performance of the medical device by clinical exam and patients' degree of satisfaction related to the use of the medical device.

Read the detailed description

Identifying premalignant and benign diseases of the cervix and selecting an appropriate treatment path can be challenging. The adult uterine cervix may exhibit a wide variety of pathologic conditions that include benign entities (eg, cervicitis, hyperplasia, nabothian cysts, cervical polyps, leiomyomas, endometriosis, and congenital abnormalities) as well as malignant lesions, particularly cervical carcinoma.

Cervical lesions range from being visible only with an instrument that augments sight such as a colposcope to being visible by speculum examination or endovaginal ultrasound.

The most frequent types of cervical lesions are:

  1. Cervical polyp Cervical polyps are benign growths, usually protruding from the surface of the cervical canal. They commonly occur during the reproductive years, especially in women over 20 years of age. Cervical polyps are the most common non-cancerous tumour of the cervix.

The cervical polyps may vary in size, shape, and origin. They can present as single or multiple, tear-shaped or lobular, cherry-red, or greyish-white in color, depending on the vascularity of the lesion. The size of the cervical polyp is typically less than three cm in diameter; however, as mentioned earlier, they can vary in size and can be large enough to fill the vagina or be present at the introitus They usually originate in the endocervical canal. Endocervical polyps may be caused by chronic inflammation. They rarely become malignant.

Nabothian cyst Nabothian cysts are a benign gynecological condition in reproductive age without clinical significance. These cysts are at the squamocolumnar junction of the uterine cervix, which is the targeted anatomical area of brush sampling at the time of cervical screening cytology. They are filled with mucus, but they may also contain proteinaceous material, neutrophils, or neutrophil debris. These cysts usually appear superficially and are easily recognized during colposcopy examination. If left untreated, they can induce considerable enlargement of the cervix, which can lead to symptomatology. Other causes of these large cysts include cystic degeneration of uterine leiomyoma and congenital uterine cysts such as mesonephric and paramesonephric cysts and cystic adenomyosis.

Complications of Nabothian cysts include hematometra, labor passage obstruction, rectal compression, abnormal uterine bleeding, specifically in case of giant cysts, and chronic urinary retention by restricting the bladder's outlet or by compressing the pudendal and sacral nerves, thus, disturbing the nerve supply to the detrusor muscle.

Cervical fibroid Cervical fibroids (myomas) start in the muscle tissue of the cervix. They are similar to uterine fibroids but less common. Cervical fibroids may not cause symptoms. The most common symptom is abnormal vaginal bleeding. Pain during intercourse may happen. If the fibroid becomes large, it may partially block the urinary tract and cause urinary drainage problems such as dribbling or urinary retention. If myomas become infected, they may cause pain, bleeding, or a discharge from the vagina.

The recommended treatment in all cases is excision. After surgery, haemostasis and rapid recovery should be promoted with the support of local, re-epithelizing treatments.

Cerviron® ovules Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.

Bismuth subgallate causes shrinkage of damaged tissue by stopping bleeding and promoting tissue healing. Being an insoluble salt and very little absorbed the bismuth subgalate forms a protective film that allows the other components to act locally. "Through its active ingredient, Bismuth subgallate, Cerviron® ovules exert a protective action on mucous membranes and raw surfaces. Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations.

The Marigold extract (Calendula Officinalis) contains as active principles carotenoid substances, triterpenic compounds and volatile oil, favouring a healing, antitricomonazic effect and reducing the excessive secretion (leucorrhea). Flavonoids and triterpene glycosides boast soothing properties and also help improve microcirculation. Marigold is mainly used for treating skin disorders: irritation, redness and inflammation. The plant was employed in the civil war to treat wounds.

This is the second clinical investigation on human subjects with this medical device, in which 50 patients will be enlisted, and which will take place in two research centres in Romania.

Conditions
Cervical Lesion
Being tested
Cerviron
Keywords
cervical lesion

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CervironDevice

    Cerviron® ovules is a class IIb medical device used as adjuvant treatment in cervical lesions of mechanical origin. It favors the healing and re-epithelialization processes and reduces the proliferation of endogenous pathogens.

    Moreover, it provides a strong hemostatic effect, as shown in multiple studies. Moreover, it contains collagen with nutritive, hydrating, healing and trophic effect. Collagen is structurally and functionally a key protein of the extracellular matrix which is also involved in forming the scars during the healing of conjunctive tissues, due to its chemotactic role. Many collagen bandages were developed to improve the repair of the wound, especially of non-infected, chronic, idle cutaneous ulcerations.

Study groups in NCT04735718
Study groupRoleWhat they receive
Cerviron vaginal ovulesExperimentalSince Cerviron® has an innovative composition, we preferred an exploratory approach for the design of the present clinical investigation. The main objectives and clinical endpoints are the performance and the safety profile of the investigational device.
Receives: Device: Cerviron

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Clinical Performance Assessed by the Investigator by Colposcopy at End of Treatment Visit

    Evolution of cervical lesions at End of Treatment Visit

    Measured: 3 months

  2. Rate of treatment-related Adverse Events in subjects participating in the clinical investigation

    Number and degree of AE

    Measured: 3 months

Secondary outcomes (3)
  1. The Re-epithelialization degree of the cervical mucosa by thorough gynaecological examination (visual evaluation)

    Gynecological examination by speculum at 1, 2 and 3 months

    Measured: at 1, 2 and 3 months

  2. Evolution of vaginal symptoms and discomfort

    Presence/absence of symptoms such as pain and/or bleeding at 1, 2 and 3 months

    Measured: at 1, 2 and 3 months

  3. Patient Satisfaction (Likert Scale)

    5 point Likert scale to evaluate the degree of satisfaction after the treatment

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Feb 2021
  2. Study start1 Aug 2021
  3. Primary completion6 Jan 2023
  4. Study completion16 Jan 2023

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
A Prospective, Open-Label, Pilot, Multicentric Clinical Investigation
Masking
None (open label)
Enrolment
27 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04735718
Sponsor's protocol ID
CYRON/02/2021
Status last verified
Jan 2023
First submitted
29 Jan 2021
Last updated
20 Jan 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Petre I, Toader DO, Petrita R, Pinta AR, Alexa AA, Bita RG. Clinical Performance and Safety of Cerviron(R) Vaginal Ovules in the Management of Symptomatic Cervical Lesions: A National, Multicentric Study. Curr Ther Res Clin Exp. 2024 Oct 9;101:100762. doi: 10.1016/j.curtheres.2024.100762. eCollection 2024.

    PubMed 39717511

Questions about this trial

What is this clinical trial studying?

A study testing Cerviron in people with Cervical Lesion, run by Perfect Care Distribution at 3 sites in Romania.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Jan 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in Romania. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Clinical Performance Assessed by the Investigator by Colposcopy at End of Treatment Visit (time frame: 3 months). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04735718, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in